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Background
This study investigates pharmacogenetic risk factors for bone mineral (apparent) density
(BM(A)D) and body composition in pediatric acute lymphoblastic leukemia
Design and Methods
We determined the influence of SNPs in 4 genes (vitamin-D receptor (VDR: BsmI/ApaI/TaqI and
Cdx-2/GATA), collagen type I alpha 1 (SpI), estrogen receptor 1 (ESR1: PvuII/XbaI), glucocorticoid
receptor (BclI)) on body composition, BM(A)D and fracture risk during dexamethasone-based
pediatric acute lymphoblastic leukemia treatment. Body composition and BMD were meas-
ured repeatedly during and after treatment using dual energy X-ray absorptiometry. 
Results
Non-carriers of VDR 5’-end (Cdx-2/GATA) haplotype 3 revealed a significant larger fat gain than
carriers (D%fat: non-carriers: +1.76SDS, carriers: +0.77SDS, P<0.001). At diagnosis and during
therapy, lumbar spine BMD was significantly higher in non-carriers of VDR 5’-end (Cdx-
2/GATA) haplotype 3 than in carriers. The other SNPs did not influence BMD or fracture risk
during/after treatment. The year after treatment completion, lean body mass increased in non-
carriers of ESR1 (PvuII/XbaI) haplotype 3 and decreased in carriers (D lean body mass: non-car-
riers:+0.28SDS, carriers: -0.55SDS, P<0.01). 
Conclusions
Only VDR 5’-end (Cdx-2/GATA) haplotype 3 was identified as protective factor against exces-
sive fat gain and as a risk factor for lower lumbar spine BMD during treatment. Carrying ESR1
(PvuII/XbaI) haplotype 3 negatively influenced recovery of lean body mass after pediatric acute
lymphoblastic leukemia treatment.
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Introduction
As the cure rate of pediatric acute lymphoblastic
leukemia (ALL) is high,1 research on treatment-related
morbidity, like disturbance of body composition and bone
mineral density (BMD), is required.2-4 Leukemia and its
treatment, especially corticosteroids5 and methotrexate,6
may lead to reduced BMD. However, uniformly treated
children show a large variation in disturbance of body
composition, BMD reduction and fractures, suggesting a
role for pharmacogenetics in the pathogenesis of these
problems.4
Several single nucleotide polymorphisms (SNPs) have
been shown to influence BMD in adults, especially those
of the vitamin-D receptor gene (VDR).7-12 The extent of the
influence of VDR SNPs on BMD may be dependent on age
and menopausal state.13 In healthy children, only a few
studies on the influence of VDR 3’-end SNPs (BsmI, ApaI,
TaqI) on BMD have been reported, with conflicting
results.14-17 Effects of VDR 5’-promoter SNPs (Cdx-2,
GATA) on BMD have not been investigated in healthy
children. With regards to body composition (muscle
strength and fat mass), it has been demonstrated that the
VDR BsmI SNP determines body composition in pre-
menopausal women.18
Another polymorphism frequently reported to be asso-
ciated with a low BMD for chronological age is the GÆT
substitution in the Sp1 binding site of the collagen type I
alpha 1 gene (COLIA1). This can result in increased
expression of collagen type I alpha 1 in the bone matrix.7,
19-21 Studies regarding the relationship between BMD and
carrying COLIA1 risk alleles in healthy children show con-
flicting results.22-25
Haplotypes of the 5’-end of the estrogen receptor alpha
gene (ESR1) in which the risk alleles of the PvuI and XbaII
SNPs are combined are associated with decreased BMD
and fractures in post-menopausal women.26-28 Only a few
studies in healthy children have been carried out, showing
conflicting results concerning the influence of ESR1 risk
alleles on BMD.25, 29 On the other hand, the PvuII and XbaI
SNPs are not related to body composition in healthy chil-
dren.30
In healthy adults, it has been suggested that polymor-
phisms in the glucocorticoid receptor gene (GR), like BclI
and N363S, modulate corticosteroid sensitivity.31,32 This in
turn could result in reduced BMD32,33 and disturbed body
composition.31,34 Since corticosteroids are considered to
cause altered body composition and reduced BMD, we
hypothesize that GR SNPs may influence variation in
body composition and BMD in pediatric ALL.
To our knowledge, this is the first study investigating the
influence of genetic variation of the VDR, COLIA1, ESR1
and GR on BMD, body composition and fracture risk in
pediatric ALL patients during and after therapy. The aim of
this study is to identify patients at risk for a low BMD for
chronological age and a disturbed body composition, in
order to develop early preventative interventions.
Design and Methods
Patients
In this prospective study, children with newly diagnosed ALL
were treated according to the dexamethasone-based protocol of
the Dutch Childhood Oncology Group (DCOG-ALL9).35 High-
risk criteria were white blood cell count of 50¥109/L or over, T-cell
immunophenotype, mediastinal mass, central nervous system
involvement, testes infiltration, t(9;22) and 11q23/MLL gene
rearrangements. The treatment schedules included dexametha-
sone given in repetitive pulses (cumulative dose: 1,244 mg/m2
(high-risk) and 1,370 mg/m2 (non-high risk). Total cumulative dose
of methotrexate was 13,650 mg/m2 in the high-risk protocol and
8,100mg/m2 in the non-high risk protocol. No patient received
central nervous system irradiation. 
To determine a potential selection bias, we compared patient
characteristics of participants of the current study with those of
the total Rotterdam DCOG-ALL9-treated cohort. The Medical
Ethical Committee approved the study. Written informed consent
according to the Helsinki agreement was obtained from all parents
and patients aged 12 years and older.
Polymorphisms
After reaching complete remission, germ-line genomic DNA
was extracted from a minimum of 5.0¥106 peripheral blood
mononuclear cells using TRIzol reagent (Gibco BRL,Life
Technologies) according to the manufacturer’s protocol. The DNA
was quantified using spectrophotometry. Figure 1 shows positions
of the SNPs which were detected by real-time PCR and hybridiza-
tion probes (Taqman).
We determined three SNPs at the 3’-end of the VDR gene (BsmI
(E8-G+284A, rs1544410), ApaI (E9-T-48G, rs739837), and TaqI (E9-
T32C, rs731236). 12 Haplotypes were named as previously
described.9,12 In our patients, haplotype 1 (baT), haplotype 2 (BAt),
haplotype 3 (bAT) and haplotype 4 (BAT) occurred, which com-
bined to eight genotypes encoded 1/1, 1/2, 1/3, 1/4, 2/2, 2/3, 2/4
and 3/3 (3/4 and 4/4 were not observed).
Two other VDR 5’-promoter region SNPs were studied; the
GÆA substitution in the Cdx-2 binding site (1e-G-1739A,
rs11568820) and an AÆG substitution in the GATA binding site
(1a-A-1012G, rs4516035)[8, 9, 36]. Both 5’-promoter polymor-
phisms were combined to haplotype 1 (GA), haplotype 2 (GG)
and haplotype 3 (AG), combining to six genotypes encoded as 1/1,
1/2, 1/3, 2/2, 2/3 and 3/3.
The Sp1 polymorphism is a GÆT substitution affecting a bind-
ing site of the Sp1 transcription factor in the first intron of COLIA1
(int1-G+1245T, rs1800012).37 The polymorphism results in three
genotypes GG, GT and TT.
We genotyped two polymorphisms in the first intron of ESR1:
PvuII (int1-T-397C, rs2234693) and XbaI (int1-A-351G,
rs9340799).28 Three haplotype alleles were encoded as haplotype
1 (px), haplotype 2 (PX), and haplotype 3 (pX), combining to six
genotypes 1/1, 1/2, 1/3, 2/2, 2/3 and 3/3.
We determined two SNPs of the GR: the BclI (int2-C-646G, rs
not available) which combined to the genotypes CC, CG and GG
and the N363S (e2-A1218G, rs6195) combining to the genotypes
AA, AG and GG.38
End points
Anthropometry data were measured in all patients. Height was
measured with a Harpenden stadiometer and weight with stan-
dard clinical scales. The body mass index (BMI) was calculated as
weight/height2. Height and BMI of the patients were compared
with reference values of healthy controls matched for age and sex
and expressed as standard deviation scores (SDS).39,40
In patients aged four years and older, dual energy X-ray
absorptiometry (DXA, Lunar DPX-L) provided estimates of lean
body mass (LBM), percentage fat of the total body (%fatTB),
BMD of the total body (BMDTB) and BMD of the lumbar spine
(BMDLS). To correct for bone size, we calculated bone mineral
apparent density (BMAD) of the lumbar spine with the model
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BMADLS=BMDLSx(4/(πxwidth)). ‘Width’ is the mean width of
the second to the fourth lumbar vertebrae. This model was val-
idated by in vivo volumetric data obtained from magnetic reso-
nance imaging.41 All DXA results were expressed as age-
matched and sex-matched SDS.42 Special pediatric software was
used for children who weighed less than 30 kg.
Symptomatic fractures, confirmed by radiography, were regis-
tered.  Fracture incidence rates of the various allelic variants were
calculated. In addition, incidence-rate ratios for non-carrier versus
carriers were calculated. 
Habitual physical activity measured in minutes/week included
physical education classes, organized sports, recreational activi-
ties, habitual walking/ cycling. 43 Calcium intake was determined
by a detailed food-frequency questionnaire of dairy products.44
Serum calcium, 1,25-dihydroxy-vitamin D and PTH were
assessed. Since over time, PTH concentrations were measured on
three different immunoanalyzers, concentrations of PTH were
expressed as the number of standard deviations above the upper
limit of the reference range of the immunoassay used.45
Measurements were performed at diagnosis, after 32 weeks,
one year, two years (completion of therapy) and three years (one
year after completion of therapy). Differences between non-carri-
ers and carriers in change of end points during the two-year treat-
ment period (D1) and during the first year after completion of
chemotherapy (D2) were investigated. To compare positions of the
curves of the different carrier groups, areas under the curves were
calculated.
Statistical analysis
SNPs were tested for deviation from the Hardy Weinberg
Equilibrium (HWE) by comparing the observed and expected
genotype frequencies using a c2 test. We calculated areas under
the curves using the trapezium rule. A Mann-Whitney U-test/c2-
test was used to compare baseline patient characteristics and
areas under the curves for the different carrier groups.
Anthropometry, body composition and BMD at diagnosis were
compared with normal reference values using a one-sample t-
test. Fracture incidence-rate ratios were tested using Poisson sta-
tistics. These statistical analyses were performed with SPSS 15.0
(SPSS Inc. Chicago, IL, USA). Differences between the carrier
groups in changes of end points (D1 and D2) were analyzed using
repeated measurements analysis (SAS PROC MIXED, SAS
Institute Inc., North Carolina, USA), with an unstructured
repeated covariance type. We pooled heterozygous and
homozygous carriers under a dominant inheritance model. In
view of the multiple comparisons, P values of ≤0.01 were con-
sidered to be significant. All analyses were carried out according
to the intention-to-treat principle; for children who did not com-
plete the study, data prior to elimination were included.
Results
Patients
Sixty-nine patients (39 males) were included, with a
mean age of 7.4 (range 1.6-16.8) years. Twenty patients
were treated with the high-risk protocol and the remain-
ing children received non-high risk treatment. Age, gender
and risk-group stratification of the included patients was
similar to that of the total DCOG-ALL9-treated cohort,
which indicated that the sample constituted a representa-
tive selection of the Rotterdam cohort.
Genotype distribution 
The distribution of the genotypes of VDR 3’-end
(BsmI/ApaI/TaqI) and 5’-end (Cdx-2/GATA), COLIA1 (Sp1),
ESR1 (PvuII/XbaI), and GR (BclI) were in HWE (Table 1).
No homozygous carriers and only 3 heterozygous carriers
of the GR (N363S) polymorphism were determined (data
not shown).
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Figure 1. Genomic structure and
positions of the single nucleotide
polymorphisms investigated in
current study. (A) The vitamin-D
receptor gene (VDR). (B) The colla-
gen type I a 1 gene (COLIA1). (C)
The estrogen receptor a gene
(ESR1). (D) The glucocorticoid
receptor gene (GR). UTR: untrans-
lated region; chr.: chromosome. 
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Baseline data
At diagnosis, there was no difference in %fatTB of our
sample compared with that of healthy peers. The patients
showed a lower BMI and LBM at diagnosis than healthy
peers (BMI=-0.51SDS, P<0.01 and LBM=-0.67SDS,
P<0.001). There was no difference in baseline BMDTB of
our ALL patients compared with healthy peers, whereas
BMDLS of the patients was lower than BMDLS of healthy
peers (BMDLS=-0.53SDS, P=0.01). However, after correc-
tion for bone size, the calculated BMADLS showed no dif-
ferences between patients and healthy peers (BMADLS=-
0.21SDS, P=0.25). 
There was no significant difference in baseline anthro-
pometry, body composition and BM(A)D between non-
carriers and carriers of any of the SNPs or haplotypes. In
addition, there were no significant differences in age, cal-
cium intake and physical activity.
Body composition during/after therapy
During treatment, the whole group of patients showed
an increase in BMI (D1BMI=+1.43SDS, P<0.001).
Consequently, BMI became higher than BMI of healthy
peers (area under the curve during treatment: P<0.001).
There was no difference in increase of BMI during treat-
ment between non-carriers and carriers of the different
allelic variants (Table 2). After completion of treatment,
Pharmacogenetic risk factors for altered bone mineral density 
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Table 1. Genotype distribution in pediatric ALL patients.
VDR 3’-end (BsmI/ApaI/TaqI) VDR 5’-end (Cdx-2/GATA) COLIA1 (Sp1) ESR1 (PvuII/XbaI) GR (BclI)
Genotype Haplotype N % Genotype Haplotype N % Genotype N % Genotype Haplotype N % Genotype N %
code code code
baT-baT 1/1 17 25 GA-GA 1/1 13 20 GG 49 73 px-px 1,1 20 29 CC 20 41
baT-BAt 1/2 16 23 GA-GG 1/2 19 30 GT 17 25 px-PX 1,2 29 43 CG 22 45
baT-bAT 1/3 8 12 GA-AG 1/3 15 23 TT 1 2 px-Px 1,3 4 6 GG 7 14
baT-BAT 1/4 2 3 GG-GG 2/2 5 8 PX-PX 2,2 10 15
BAt-BAt 2/2 14 21 GG-AG 2/3 9 14 PX-Px 2,3 4 6
BAt-bAT 2/3 5 7 AG-AG 3/3 3 5 Px-Px 3,3 1 1
Bat-BAT 2/4 4 6
bAT-bAT 3/3 2 3
Total 68 64 67 68 49
HWE P value 0.30 0.72 0.73 0.84 0.36
VDR: vitamin D receptor gene; COLIA1: collagen type I a 1 gene; ESR1: estrogen receptor a gene; GR: glucocorticoid receptor gene; N: number; HWE: Hardy Weinberg equilibrium.
Table 2. Change of anthropometry, bone mineral density and body composition for the investigated genetic variations of the VDR, COLIA1, ESR1 and GR genes.
VDR 3’-end (BsmI/ApaI/TaqI) VDR 5’-end (Cdx-2/GATA) COLIA1 (Sp1) ESR1 (PvuII/XbaI) GR (BclI)
Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 1 Haplotype 2 Haplotype 3
Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier Non Carrier
carrier carrier carrier carrier carrier carrier carrier carrier carrier carrier carrier
D1
Height (SDS) -0.56 -0.65 -0.68 -0.57 -0.64 -0.54 -0.87 -0.51** -0.54 -0.66 -0.56 -0.66 -0.60 -0.68 -0.55 -0.64 -0.65 -0.60 -0.62 -0.64 -0.44 -0.62
BMI (SDS) 1.30 1.51 1.55 1.36 1.49 1.24 0.99 1.48 1.39 1.33 1.58 1.05 1.50 1.36 1.23 1.50 1.78 1.24 1.38 1.81 1.11 1.48
BMDLS (SDS) 0.17 -0.32 -0.33 -0.03 -0.08 -0.44 -0.36 -0.19 -0.15 -0.29 -0.08 -0.40 -0.04 -0.44 -0.57 -0.03 -0.14 -0.16 -0.02 -1.09 -0.18 0.06
BMADLS (SDS)-0.01 -0.40 -0.28 -0.25 -0.34 0.01 -0.48 -0.26 -0.39 -0.22 -0.11 -0.57 -0.26 -0.28 -0.50 -0.19 -0.29 -0.25 -0.20 -0.64 -0.24 0.03
BMDTB (SDS) -0.68 -1.20 -1.33 -0.78 -0.97 -1.15 -1.06 -1.08 -0.99 -1.17 -0.96 -1.23 -0.96 -1.13 -1.62 -0.82 -0.76 -1.13 -0.91 -1.72 -1.40 -0.80
%fatTB (SDS) 1.09 1.50 1.51 1.25 1.31 1.50 0.59 1.47** 1.25 1.39 1.76 0.77* 1.44 1.13 1.13 1.44 1.61 1.22 1.36 1.40 1.47 1.15
LBM (SDS) 0.09 -0.40 -0.46 -0.06 -0.20 -0.34 -0.34 -0.20 -0.07 -0.45 -0.25 0.24 -0.19 -0.30 -0.32 -0.20 -0.12 -0.28 -0.22 -0.36 -0.33 -0.10
D2
Height (SDS) 0.42 0.16 0.24 0.26 0.14 0.56** 0.61 0.10* 0.09 0.36 0.28 0.20 0.14 0.30 0.00 0.32 0.19 0.29 0.28 0.04 0.29 0.27
BMI (SDS) -0.13 -0.45 -0.34 -0.33 -0.43 -0.02 -0.23 -0.38 -0.30 -0.38 -0.58 0.00† -0.35 -0.26 -0.29 -0.35 -0.42 -0.28 -0.28 -0.76 -0.01 -0.19
BMDLS (SDS) -0.01 0.02 -0.02 0.02 -0.06 0.24 -0.02 0.02 -0.02 0.04 -0.12 0.17 0.09 -0.17 0.37 -0.09** -0.11 0.07 0.00 0.02 -0.09 0.11
BMADLS (SDS)-0.17 -0.23 -0.20 -0.21 -0.17 -0.31 -0.36 -0.15 -0.11 -0.31 -0.31 -0.11 -0.06 -0.55** -0.11 -0.24 -0.25 -0.20 -0.23 0.12 -0.24 -0.23
BMDTB (SDS) 0.44 0.22 0.21 0.37 0.25 0.45 0.54 0.23 0.32 0.30 0.18 0.46 0.36 0.15 0.50 0.24 0.27 0.31 0.27 0.55 0.15 0.36
%fatTB (SDS) -0.32 -0.79 -0.63 -0.63 -0.73 -0.27 -0.66 -0.66 -0.49 -0.81 -0.85 -0.42 -0.54 -0.84 -0.32 -0.73 -0.81 -0.55 -0.61 -0.88 -0.55 -0.46
LBM (SDS) 0.23 0.22 0.26 0.18 0.12 0.57** 0.61 0.10** 0.03 0.42** 0.11 0.38 0.16 0.37 0.22 0.23 0.11 0.29 0.28 -0.55* 0.38 0.28
VDR: vitamin-D receptor gene; COLIA1: collagen type I alpha 1 gene; ESR1: estrogen receptor alpha gene; GR: glucocorticoid receptor gene; D1: change during treatment; D2=change after treatment
discontinuation; SDS: standard deviation score; BMI: body mass index; BM(A)DLS: bone mineral (apparent) density of the lumbar spine; BMDTB: bone mineral density of the total body; %fatTB:
percentage of fat of the total body; LBM: lean body mass. Values are expressed as mean DSDS. Difference between non-carriers and carriers: *P≥0.01 and **0.01<P<0.05 (ANOVA).
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BMI of the patients decreased (D2BMI=-0.31SDS, P<0.01),
but remained higher than BMI of healthy peers one year
after completion of treatment (BMI=+0.60SDS, P<0.001).
Furthermore, there was no influence of the carrier status
of any of the genotypes on change of BMI after treatment.
There were no differences between non-carriers and carri-
ers of the investigated risk alleles in the areas under the
curves of BMI either during treatment or during the year
after treatment.
During treatment, %fatTB in the patient group was high-
er than in healthy peers (area under the curve during treat-
ment: P<0.001) and increased significantly
(D1%fatTB=+1.32SDS, P<0.001). After completion of treat-
ment, %fatTB in the whole study group decreased
(D2%fatTB=-0.60SDS, P<0.001), but remained higher than
in healthy peers (%fatTB=+0.64SDS, P<0.001). A signifi-
cant difference in gain of %fatTB during treatment was
found between non-carriers and carriers of the VDR 5’-end
(Cdx-2/GATA) haplotype 3 (non-carriers:
D1%fatTB=+1.76SDS, carriers D1%fatTB=+0.77 SDS;
P<0.001) (Table 2). This difference in fat gain between
both groups was not evident in the first eight months of
treatment, but became obvious during the remaining part
of the treatment. No differences in D1%fatTB between non-
carriers and carriers of any of the other investigated risk
alleles were found. Furthermore, D2%fatTB of the non-car-
riers of the investigated SNPs/ haplotypes was similar to
that of the carriers. There was no difference in the areas
under the curve of %fatTB between the various carrier
groups during treatment or in the year after treatment.
During treatment, the whole group of patients had a
lower LBM than healthy peers (area under the curve dur-
ing treatment: P<0.001) and it showed no significant
change during treatment. In addition, non-carriers showed
the same development of LBM during treatment as carri-
ers of the different risk alleles (Table 2). Although LBM of
the whole group increased in the year after completion of
treatment (D2LBM=+0.23SDS, P<0.01), LBM remained
lower than in healthy peers (LBM=-0.69SDS, P<0.001).
The first year after treatment completed, LBM increased in
non-carriers of ESR1 (PvuII/XbaI) haplotype 3, but not in
carriers (non-carriers: D2LBM=+0.28SDS, carriers:
D2LBM=-0.55SDS; P<0.01). There was no difference in the
D2LBM between non-carriers and carriers of the other
investigated risk alleles. During treatment and during the
year after treatment, there was no difference in the areas
under the curves of LBM between the various carrier
groups.
BMD during/after therapy
During treatment, BMDLS of the patients remained
lower than that of healthy peers (P<0.01). As BMDLS of the
whole group did not change either during or after treat-
ment, a year after completion of treatment it was still
lower in the patients than in healthy peers (BMDLS=-
0.63SDS, P<0.001). BMADLS was only lower in patients
than in healthy peers after completion of treatment
(P<0.01). 
Figure 2 shows the effect of different haplotypes of the
VDR 5’-end (Cdx-2/GATA) on BM(A)DLS. Carriers of the
VDR 5’-end haplotype 3 had a lower BMDLS and BMADLS
than non-carriers (area under the curve BMDLS: P=0.01,
area under the curve BMADLS: P=0.03). There was no dif-
ference in BM(A)DLS between non-carriers and carriers of
haplotype 1 (area under the curve BMDLS: P=0.68, area
under the curve BMADLS: P=0.98) or haplotype 2 (area
under the curve BMDLS: P=0.91, area under the curve
BMADLS: P=0.92) of the VDR 5’-end. No differences in
areas under the curves of BM(A)DLS were found between
non-carriers and carriers of the other investigated risk alle-
les. Moreover, no differences were shown for D1BM(A)DLS
and D2BM(A)DLS between non-carriers and carriers of the
M.L. te Winkel et al.
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Figure 2. Bone mineral (apparent) density of the lumbar spine in non-carriers versus carriers of haplotypes of the VDR 5’-end (Cdx-2/ GATA)
(mean ± SEM) BM(A)DLS: bone mineral (apparent) density of the lumbar spine; SDS: standard deviation score, non-carrier=—n—, carrier=--
s--, *=significant different from 0.
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SNPs/ haplotypes (Table 2).
During treatment, BMDTB decreased in patients
(D1BMDTB=-1.00SDS, P<0.001). One year after diagnosis,
the total group of patients developed lower levels of
BMDTB than healthy peers (P<0.01). During the year after
treatment, BMDTB of the patients increased
(D2BMDTB=+0.29SDS, P<0.001), but remained lower than
that of healthy peers (BMDTB=-0.52SDS, P<0.001). No sig-
nificant differences in D1BMDTB or D2BMDTB between non-
carriers and carriers of the VDR, COLIA1, ESR1 or GR risk
alleles were found (Table 2). In addition, there was no dif-
ference in areas under the curves of BMDTB between the
various carrier groups either during treatment or during
the year after completion of treatment.
Fractures
Nine patients sustained a fracture during therapy (n=5)
or within one year after completion of treatment (n=4).
Fractures involved the forearm (n=4), the tibia (n=3), the
clavicle (n=1) and a vertebra (n=1). Except for the vertebral
compression fracture, all fractures were preceded by
minor trauma. The investigated SNPs/ haplotypes were
not associated with an increased fracture risk (Figure 3).
Biomarkers
No differences in serum calcium, PTH and 1,25-dihy-
droxy-vitamin D were found between non-carriers and
carriers of the VDR 5’-end (Cdx-2/GATA) haplotype 3
(Table 3). Moreover, there was no difference in the change
of calcium, PTH and 1,25-dihydroxy-vitamin D during
therapy and during the year after treatment between non-
carriers and carriers of the VDR 5’-end haplotype 3. 
Discussion
Body composition and polymorphisms
None of the genetic variations in the investigated genes
(VDR, COLIA1, ESR1 and GR) influenced body composi-
tion during pediatric ALL treatment, except for haplotype
3 of the VDR 5’-promoter region (Cdx-2/GATA). Non-car-
riers of the VDR 5’-end haplotype 3 had a larger gain of
body fat during treatment than carriers, suggesting a role
for vitamin D in the regulation of body fat during pediatric
ALL treatment. The Cdx-2 A-allele increases VDR tran-
scription in the small intestine and may consequently
increase calcium absorption.36 Therefore, we hypothe-
sized that non-carriers of the VDR 5’-end haplotype 3
(without the Cdx-2 A-allele) may have relatively lower
serum calcium resulting in a relative hyperparathyroidism.
This could lead to increased intracellular calcium within
adipocytes, inducing lipogenesis.46 However, we found no
significant differences in serum calcium or PTH between
non-carriers and carriers of the VDR 5’-end haplotype 3.
Therefore, it is questionable whether this mechanism
indeed plays a role in regulation of body fat during ALL
treatment in children.
The current study suggests that carrying ESR1
(PvuII/XbaI) haplotype 3 negatively influences recovery of
LBM after completion of treatment, whereas none of the
other genes (VDR, COLIA1 and GR) influence body com-
position after ALL treatment. In adults, polymorphisms in
ESR1 have been described to be associated with measures
of adiposity,47 although studies on the influence of ESR1
on LBM are not available. In healthy children, the PvuII
and XbaI SNPs were not related to body composition.30
BMD and polymorphisms
We found a lower BMDLS in patients carrying the VDR
5’-end (Cdx-2/GATA) haplotype 3 than in non-carriers,
which was already present at diagnosis. Despite this
lower BMDLS, carriers of the VDR 5’-end haplotype 3 did
not show a larger treatment-related loss of BMDLS. Two
previous reports showed that presence of the Cdx-2 A-
allele protected against the loss of BMD and subsequent
osteoporotic fractures in elderly individuals.8,36 This illus-
trates that aging may influence the effect of genetic varia-
tion on BMD.48 Moreover, the present study reports on
genotype-based differences in the development of BMD
following ALL treatment, while the majority of adult
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Figure 3. Fracture incidence-rate ratios for non-carriers versus carri-
ers of the different allelic variants. IRR: incidence-rate ratio;  VDR:
vitamin-D receptor gene; COLIA1: collagen type I a 1;  ESR1: estro-
gen receptor a gene; GR: glucocorticoid receptor gene, hap: haplo-
type. 
Table 3. Biochemical markers in non-carriers and carriers of the VDR
5’-end haplotype 3. 
VDR 5’-end (Cdx-2/GATA) 
Haplotype 3 
Non- Carrier P P
carrier of change 
Calcium  (mmol/L) 
Diagnosis  2.30 2.29 0.87 
Cessation of treatment  2.36 2.36 0.93 D1: 0.84 
1 Year after cessation of treatment  2.38 2.37 0.78 D2: 0.81 
PTH (SD above upper limit)
Diagnosis  -2.93 -2.05 0.17 
Cessation of treatment -1.90 -1.09 0.26 D1: 0.92 
1 Year after cessation of treatment  -0.54 -0.52 0.98 D2: 0.27 
1,25-dihydroxy-vitamin D (pmol/L) 
Diagnosis 107.2 104.8 0.88 
Cessation of treatment 134.4 128.3 0.70 D1: 0.86 
1 Year after cessation of treatment  134.5 145.9 0.25 D2: 0.30 
VDR: vitamin-D receptor gene, D1:change during treatment, D2:change after treatment;
discontinuation, SD: standard deviation.
VDR 3’ (Bsml/Apal/Taql) hap 1
VDR 3’ (Bsml/Apal/Taql) hap 2
VDR 3’ (Bsml/Apal/Taql) hap 3
VDR 5’ (Cdx-2/GATA) hap 1
VDR 5’ (Cdx-2/GATA) hap 2
VDR 5’ (Cdx-2/GATA) hap 3
COLIA1 (Sp1)
ESR1 (Pvull/Xbal) hap 1
ESR1 (Pvull/Xbal) hap 2
ESR1 (Pvull/Xbal) hap 3
GR (Bcl1)
Fracture incidence rate ratio
Fracture IRR, 95% confidence interval
-5 0 1 5 10 15
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reports examined BMD differences between genotypes
without chemotherapy.
We did not find any association between VDR 3’-end
(BsmI/ApaI/TaqI) haplotypes and BMD. This is in line with
the fact that VDR BsmI and ApaI SNPs did not influence
corticosteroid-induced bone loss in adults receiving corti-
costeroids for rheumatoid arthritis.49 No studies are avail-
able on the effects of the VDR 3’-end SNPs on BMD in
ALL patients treated with corticosteroids. Studies on the
relation between BMD and VDR 3’-end SNPs in healthy
children show conflicting results that may be explained by
gene-environment interactions, like dietary calcium
intake.48,50 In the current study however, calcium intake
was adequate with no difference between non-carriers
and carriers. Moreover, physical activity could interact
with the gene-effect, although there was no difference
between non-carriers and carriers. The fact that the indi-
viduals in whom the questionnaire was validated had a
higher age than our studied ALL patients may have
masked a possible gene-physical activity interaction.
We found no influence of polymorphisms of the
COLIA1 (Sp1), ESR1 (PvuII/XbaI) and GR (BclI) on
BM(A)D. Because the number of included patients was
relatively low, validation of the results in larger cohorts is
recommended to confirm our results and to exclude the
risk of false-negative findings. So far, no studies on the
influence of genetic variation of the COLIA1, ESR1 and
GR on BM(A)D have been performed in pediatric ALL
patients. Several studies in the elderly reported an associ-
ation between the Sp1 polymorphism and a lower BMD
and increased fracture risk.7,21 In pediatric populations this
association is less clear. A lower BMD in healthy children
carrying the Sp1 T-allele has been reported but this was
mainly due to differences in bone size.19,23 The effect of
the ESR1 polymorphism on steroid-induced bone loss has
not been previously described. Regarding the GR SNPs,
the N363S was associated with BMD in healthy adults.32
Our study included no homozygous and 3 heterozygous
carriers of the N363S SNP, so no conclusion could be
drawn on the effects of this SNP on BMD in pediatric
ALL. 
Fractures
The evaluated risk alleles did not influence fracture risk
in our cohort of pediatric ALL patients. This lack of asso-
ciation might be explained by other factors contributing to
fracture risk, like an increased tendency to fall due to vin-
cristine neuropathy during ALL treatment.
Conclusion
This is the first study investigating the influence of
genetic variation of the VDR, COLIA1, ESR1 and GR on
body composition, BMD and fracture risk in pediatric
ALL. We found the VDR 5’-end (Cdx-2/GATA) haplotype
3 as a protective factor for excessive fat gain during thera-
py. Moreover, this haplotype 3 of the VDR 5’-promoter
was determined as a risk factor for a lower BM(A)DLS at
diagnosis, which remained a risk factor for a lower
BM(A)DLS over the course of ALL treatment. Carriage of
ESR1 (PvuII/XbaI) haplotype 3 negatively influenced
recovery of LBM after completion of treatment. 
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